A randomized, double blinded, sham controlled phase IIb study of JVS-100 in heart failure patients with low ejection fraction and elevated serum biomarker

Trial Profile

A randomized, double blinded, sham controlled phase IIb study of JVS-100 in heart failure patients with low ejection fraction and elevated serum biomarker

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs JVS 100 (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms STOP-HF2
  • Most Recent Events

    • 18 Jun 2015 New trial record
    • 16 Jun 2015 According to a Juventas Therapeutics media release, the results of this study will help to guide the design of pivotal Phase 3 registration trials for JVS-100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top